Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
Open Access
- 1 July 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (19) , 1767-1773
Abstract
We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351 ) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD] neg ) predicted longer event-free survival (EFS) at all time points in both arms, with significantly more liso-cel–treated patients achieving MRD neg . Liso-cel demonstrated superior outcomes versus ASCT, including longer EFS, progression-free survival (PFS), and duration of response among patients in complete response (CR) and MRD neg . ctDNA re-emergence in patients with CR after ASCT confirmed its potential in predicting relapse. MRD neg remained significantly associated with EFS after adjusting for positron emission tomography (PET) response, while interaction testing revealed a significant interaction between PET status and treatment arm for EFS. Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.Keywords
This publication has 25 references indexed in Scilit:
- Regulatory implications of ctDNA in immuno-oncology for solid tumorsJournal for ImmunoTherapy of Cancer, 2023
- Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomasCancer Cell, 2022
- MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial DesignBlood, 2022
- Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trialThe Lancet, 2022
- Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational researchLeukemia, 2022
- Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual DiseaseCancer Discovery, 2021
- Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNANature Biotechnology, 2021
- Application of Cell-free DNA Analysis to Cancer TreatmentNew England Journal of Medicine, 2018
- Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapyBlood, 2016
- Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker studyThe Lancet Oncology, 2015